Your browser doesn't support javascript.
loading
Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction
Martínez-Lago, N; Vieito-Villar, M; Vidal-Insua, Y; Padin-Iruegas, ME; Vazquez-Rivera, F; Candamio-Folgar, S; Lopez-Lopez, R.
Afiliação
  • Martínez-Lago, N; Hospital Clínico Universitario. Medical Oncology Department. Santiago de Compostela. Spain
  • Vieito-Villar, M; Hospital Clínico Universitario. Medical Oncology Department. Santiago de Compostela. Spain
  • Vidal-Insua, Y; Hospital Clínico Universitario. Medical Oncology Department. Santiago de Compostela. Spain
  • Padin-Iruegas, ME; University of Vigo. Department of Functional Biology and Health Sciences. Human Anatomy and Embryology Section. Vigo. Spain
  • Vazquez-Rivera, F; Hospital Clínico Universitario. Medical Oncology Department. Santiago de Compostela. Spain
  • Candamio-Folgar, S; Hospital Clínico Universitario. Medical Oncology Department. Santiago de Compostela. Spain
  • Lopez-Lopez, R; Hospital Clínico Universitario. Medical Oncology Department. Santiago de Compostela. Spain
Clin. transl. oncol. (Print) ; 17(11): 856-861, nov. 2015. tab, ilus
Artigo em Inglês | IBECS | ID: ibc-143455
Biblioteca responsável: ES1.1
Localização: BNCS
ABSTRACT
Purpose. In high risk gastric and gastroesophageal adenocarcinoma, adjuvant radiochemotherapy with 5-fluorouracil bolus became a standard adjuvant treatment, showing significant improvement in overall survival after surgery, although with substantial toxicity. We explored the efficacy and toxicity of a modified 5-fluorouracil continuous infusion scheme. Methods. We conducted an observational retrospective study in our centre. Gastric/gastroesophageal junction adenocarcinoma patients were treated with a schedule consisting in four infusions of bolus 5-fluorouracil 400 mg/m2 iv with leucovorin 200 mg/m2 iv and 1200 mg/m2 in 46-hour infusion of 5-fluorouracil (D’Gramont scheme), followed by concomitant radiochemotherapy (45 Gy in 25 fractions of 1.8 Gy) with 5-fluorouracil continuously infusion 225 mg/m2/day and four additional infusions of chemotherapy one month after complete radiochemotherapy. Results. Between January 2007 and December 2013, 55 patients received a mean of 3.16 bi-weekly adjuvant infusions followed by 4.6 weeks of continuous treatment concurrent with radiotherapy and 3.72 bi-weekly infusions after radiotherapy treatment. During adjuvant treatment, grade III toxicity was mostly haematologic, while gastrointestinal and cutaneous toxicity was predominant during concurrent treatment. There were no grade IV- or treatment-related deaths during this study. Disease-free survival (DFS) was 79.2 months (56.3–102.1 months), and the 3-year survival rates were 52.7 %. Conclusions. This 5-fluorouracil infusional scheme has an excellent tolerability profile and favourable efficacy results (AU)
RESUMEN
No disponible
Assuntos
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Leucovorina / Quimioterapia Adjuvante / Quimiorradioterapia Adjuvante / Fluoruracila Tipo de estudo: Estudo de etiologia / Estudo observacional / Fatores de risco Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2015 Tipo de documento: Artigo Instituição/País de afiliação: Hospital Clínico Universitario/Spain / University of Vigo/Spain
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Neoplasias Gástricas / Adenocarcinoma / Leucovorina / Quimioterapia Adjuvante / Quimiorradioterapia Adjuvante / Fluoruracila Tipo de estudo: Estudo de etiologia / Estudo observacional / Fatores de risco Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2015 Tipo de documento: Artigo Instituição/País de afiliação: Hospital Clínico Universitario/Spain / University of Vigo/Spain
...